Over 200,000 ER visits a year from lows that current pumps can't prevent. A $6B+ market where no device integrates insulin, glucagon, and CGM together. Pancreum fills that gap — with a roadmap to full AI autonomy.
0M+
Americans with insulin-dependent diabetes
0K+
ER visits/year from hypoglycemia
$0B+
Global diabetes tech market
$0B
Annual cost of diabetes in the U.S.
The insulin pump market is dominated by Insulet ($2B+ revenue), Tandem ($940M), and Medtronic — yet every device shares the same fundamental gaps.
| Capability | Pancreum | Omnipod 5 | Tandem | Medtronic | iLet |
|---|---|---|---|---|---|
| Insulin Delivery | Yes | Yes | Yes | Yes | Yes |
| Glucagon Delivery | Yes | No | No | No | No |
| Integrated CGM | Yes | No | No | No | No |
| Tubeless Design | Yes | Yes | No | No | No |
| Smartphone Control | Yes | Yes | Yes | Yes | Yes |
Based on commercially available configurations. Beta Bionics iLet dual-hormone version remains in development. Tubeless pumps now capture 60% of new installations. Over 80% of new pump prescriptions bundle CGM.
Investment
De-risk with $250K seed, then scale with $4M Series A
$250K
Seed Round
$4M
Series A
TAM
9 Million
Type 1 diabetics worldwide
SAM
2.1 Million
Type 1 diabetics in the U.S.
SOM
200,000
U.S. adults with high hypoglycemia burden
Market Opportunity
Insulin delivery is a multi-billion-dollar U.S. market — yet most people who could benefit from a pump still aren't on one, and outcomes remain poor.
$12B
Total U.S. insulin-delivery market
~$6B
Type 1 diabetes segment
~1.9M
People with T1D in the U.S.
~39%
Just <10% among insulin-intensive Type 2 patients — the technology is broadly underused.
~80%
~80% of people with T1D are not at the ADA goal of HbA1c <7% — and many of those who are remain overburdened by daily management.
Complexity
Carb counting, manual correction doses, and frequent clinician adjustments make today's pumps hard to start and harder to live with.
When continuous glucose monitors removed the need for fingerstick calibration, adoption leapt from roughly 7% to 80% of people with T1D. Pumps have not had their equivalent breakthrough — penetration has crept from ~25% to just ~39% over a decade. An integrated, automated, simpler device is positioned to be that leap.
CGM Adoption
7% → 80%
after removing calibration
Pump Adoption
25% → 39%
over the same period
Sources: U.S. CDC; American Diabetes Association; Foster et al., Diabetes Technol Ther. 2019; Pettus et al., Diabetes Care 2019; publicly reported industry market data. Figures are U.S. estimates.
$400/mo
Per user — pumps + sensors
$48M
Projected revenue by Year 5
10K
Projected customers by Year 5
Year 3
Break-even — scalable U.S. manufacturing
Benchtop testing only — no human clinical trials required
Patents Filed & Issued
2014
Functional Prototype at Final Size
2023
Endocrinologist & Patient Validation
2024
30-Pump Manufacturing Run
2025
Design Freeze
Q1 2026
Testing & FDA Prep
Q2 2026
FDA 510(k) Review
Q2 2027
FDA Approval
Q4 2027
Pre-Launch
Q3 2028
Full Commercial Launch
Q4 2028
Wearable at final size with successful bench tests completed
US 9,248,235; US 11,833,328 + 1 Pending; Design Patent US D704,325
Positive feedback from endocrinologists and patients; clinical partners ready
Engineering complete; 510(k) pathway with Insulet Omnipod as predicate device
Insiders who built industry-leading pumps — now innovating beyond them
CEO & Co-Founder
Biomedical Engineer
Patent Attorney
10+ years med devices
Ex-Insulet, Bayer
VP Engineering
Pioneer of world's first
disposable insulin pump
25+ years
Ex-Insulet, Medtronic
CTO & Co-Founder
Embedded Software Engineer
25+ years experience
Ex-Insulet
Access our investor portal for detailed financials, cap table, and investment documents.